Finance Enterprise Partner Lead - Poland and SECE
No salary listed
Senior
Bachelor's, Master's, MBA
Warsaw, Poland
In PersonFlex Location permits work from different places in the world for a certain period; primary workplace is Warsaw.
Finance & BankingCorporate Finance & FP&A
About the job
Requirements
- Full proficiency in written and spoken Polish and English.
- At least 7 years of relevant commercial finance or business partnering experience.
- At least 2 years of proven leadership experience coaching and empowering high-performing teams.
- A university degree in Finance, Accounting, Business Administration, or a related field is required.
- Strong business and accounting acumen, including a solid understanding of GAAP and IFRS, and the ability to guide decisions affecting profit and loss, balance sheets, and cash flow.
- Strong analytical and data-driven problem-solving skills.
- Proven negotiation skills.
- Comfort navigating complex, agile environments and leading organizational change.
- Understanding of the local healthcare landscape and market dynamics.
Responsibilities
- Lead, develop, and coach a team of specialists and experts, creating a psychologically safe and inclusive environment.
- Empower decision-making at all levels and foster trust, autonomy, and collective accountability.
- Adapt team plans and priorities to navigate operational and resource challenges.
- Partner with commercial leadership to shape market strategies, business planning, opportunity prioritization, and revenue-generation initiatives.
- Drive commercial deals through risk evaluation, market analysis, competitor assumptions, and value-based pricing strategies.
- Support the business and customers in co-creating business models and providing financial impact metrics.
- Apply financial rigor to commercial proposals and tenders to support competitive and profitable outcomes.
- Drive profit-and-loss performance, ensure financial targets are met, and advise on corrective actions when deviations occur.
- Identify and execute profit-and-loss optimization ideas, including upsell opportunities, efficiency improvements, risk reduction, and waste elimination.
- Balance resource allocation across business priorities based on financial implications and long-term enterprise strategy.
- Monitor customer and contract performance over the full lifecycle for profitability and outcomes.
- Build networks across local, regional, and global finance communities to share best practices, use digital tools, and co-create cross-functional solutions.
- Consider upstream and downstream operational impacts across the broader healthcare ecosystem.
- Ensure financial control standards and compliance with Internal Audit, Roche Accounting Standards, and local regulations.
- Manage the license-to-operate function and lead local deployment of global infrastructure initiatives such as ASPIRE.
- Co-own subregional finance priorities with the other members of the Subregional Finance Enterprise Leads community.
- Navigate volatile macroeconomic environments to maintain profit-and-loss sustainability, mitigate financial risks, and identify growth opportunities.
- Foster continuous improvement in internal processes.
- Champion deployment of automation and artificial intelligence tools to optimize end-to-end processes.
Desired Qualifications
- A Master’s degree or MBA is preferred.
- Experience in in-vitro diagnostics, MedTech, or pharmaceuticals is highly valued.
- Passion for leveraging digital tools, data analytics, and modern technology to optimize end-to-end processes.
About the company
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Get referred to Roche
See people who can refer or advise you
Simplify's Take
What believers are saying
- Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
- pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
- Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.
What critics are saying
- Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
- Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
- If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.
What makes Roche unique
- Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
- Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
- Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Performance Bonus